A-T Superstar, Luke Ogden, is hosting the 3^rd A-T Wheelathon on Saturday 1^st of March 2025 in Melbourne.

Check out the photos from previous Wheelathons

Identifying existing drugs to repurpose for treating A-T

We are delighted to announce the commencement of a new A-T research study on 1^st November 2024 at the University of Birmingham, UK.

This is the fourth of the 5 studies comprising the 2024 A-T Global Alliance $2.5M Grant Round funded by Action for A-T (UK), The A-T Society (UK), AEFAT (Spain) and BrAshA-T.

The 32-month, $485,000 project will be led by Dr Richard Tuxworth. Read more

Development of a Gene Therapy approach to treat A-T

We are delighted to announce the commencement of a new A-T research study on 1^st September 2024 at the University of North Carolina at Chapel Hill, USA.

This is the third of the 5 studies comprising the 2024 A-T Global Alliance $2.5M Grant Round funded by Action for A-T (UK), AEFAT (Spain) and BrAshA-T.

The 36-month, $485,000 project will be led by Professor Samuel Young. Read more

Biomarkers for Babies and Young Children with A-T (BOBCAT)

We are delighted to announce the commencement of a new A-T research study on 1^st September 2024 at the University of Nottingham, UK.

This is another of the 5 studies comprising the 2024 A-T Global Alliance $2.5M Grant Round funded by Action for A-T (UK), The A-T Society (UK), AEFAT (Spain) and BrAshA-T.

The 60-month, $480,000 project will be led by Professor Rob Dineen. Read more

Functional impact of Nicotinamide Riboside on patients with A-T

We are delighted to announce the commencement of a new A-T research study on 1^st September 2024 at Leiden University Medical Center, Netherlands.

This is the first of 5 studies comprising the 2024 A-T Global Alliance $2.5M Grant Round funded by Action for A-T (UK), AEFAT (Spain) and BrAshA-T.

The 36-month, $485,000 project will be led by Dr Mirjam van der Burg. Read more

Commencement of Triheptanoin Open Label Phase

The analysis of the Triheptanoin Phase 2 Trial was published at the end of 2023 highlighting that patients demonstrated statistically and clinically meaningful improvements.

This has paved the way for the next step of the trial, the Open Label Phase which commenced in February 2024 (restricted to Australian patients).

During this 12-month phase, patients will continue the use of triheptanoin without placebo. This will also lay the groundwork for an international Phase 3 Trial subsequent to the Open Label Phase. Read more